Collins Helen Louise

Track

Insider profile

Collins Helen Louise's trades of Enliven Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-21 2026-07-17
PlS Planned sale
36,335 -46.0%
350.38
US$4,583,491 		36,335 -46.0% 350.38 US$4,583,491
2026-07-21 2026-07-17
PlS Planned sale
35,361 -16.2%
18.38
US$3,431,779 		35,361 -16.2% 18.38 US$3,431,779
2026-07-21 2026-07-17
PlS Planned sale
22,124 -32.4%
325.20
US$843,696 		22,124 -32.4% 325.20 US$843,696
2026-07-21 2026-07-17
PlS Planned sale
459 -1.5%
51.55
US$23,660 		459 -1.5% 51.55 US$23,660
2026-07-21 2026-07-17
PlS Planned sale
231 -0.8%
50.05
US$11,563 		231 -0.8% 50.05 US$11,563
2026-07-17 2026-07-17
PrS Proposed sale
15,000
50.86
US$762,900 		15,000 50.86 US$762,900
2026-06-22 2026-06-17
PlS Planned sale
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17
PlS Planned sale
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17
PlS Planned sale
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17
PlS Planned sale
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17
PlS Planned sale
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-06-22 2026-06-17
PlS Planned sale
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-05-20 2026-05-18
PlS Planned sale
223 -0.9%
41.21
US$9,189 		223 -0.9% 41.21 US$9,189
2026-05-20 2026-05-18
PlS Planned sale
1,302 -4.9%
40.25
US$52,402 		1,302 -4.9% 40.25 US$52,402
2026-05-20 2026-05-18
PlS Planned sale
3,475 -11.6%
39.53
US$137,381 		3,475 -11.6% 39.53 US$137,381
2026-05-18 2026-05-18
PrS Proposed sale
15,000
41.34
US$620,100 		15,000 41.34 US$620,100
2026-04-21 2026-04-17
PlS Planned sale
2,441 -8.9%
48.06
US$117,303 		2,441 -8.9% 48.06 US$117,303
2026-04-21 2026-04-17
PlS Planned sale
2,419 -8.1%
47.39
US$114,635 		2,419 -8.1% 47.39 US$114,635
2026-04-21 2026-04-17
PlS Planned sale
140 -0.5%
45.81
US$6,413 		140 -0.5% 45.81 US$6,413
2026-03-27 2026-03-25
PlS Planned sale
40,000 -61.5%
35.10
US$1,404,024 		40,000 -61.5% 35.10 US$1,404,024
2026-03-25 2026-03-25
PrS Proposed sale
45,000
31.15
US$1,401,750 		45,000 31.15 US$1,401,750
2026-03-19 2026-03-17
PlS Planned sale
5,000 -16.7%
27.76
US$138,800 		5,000 -16.7% 27.76 US$138,800
2026-03-11 2026-03-10
PlS Planned sale
10,129 -28.8%
30.19
US$305,827 		10,129 -28.8% 30.19 US$305,827
2026-03-11 2026-03-09
PlS Planned sale
29,871 -54.4%
30.02
US$896,811 		29,871 -54.4% 30.02 US$896,811
2026-03-09 2026-03-09
PrS Proposed sale
45,000
29.44
US$1,324,800 		45,000 29.44 US$1,324,800
2026-02-19 2026-02-17
PlS Planned sale
45,000 -64.3%
26.17
US$1,177,862 		45,000 -64.3% 26.17 US$1,177,862
2026-02-17 2026-02-17
PrS Proposed sale
45,000
26.72
US$1,202,400 		45,000 26.72 US$1,202,400
2024-10-22 2024-10-18
PlS Planned sale
816 -100.0%
30.00
US$24,482 		816 -100.0% 30.00 US$24,482
2024-10-18 2024-10-18
PrS Proposed sale
25,000
28.02
US$700,500 		25,000 28.02 US$700,500
2024-04-15 2024-04-11
PlS Planned sale
20,000 -100.0%
25.07
US$501,478 		20,000 -100.0% 25.07 US$501,478
2024-04-11 2024-04-11
PrS Proposed sale
20,000
19.82
US$396,400 		20,000 19.82 US$396,400